Phibro Animal Health Files 8-K/A Amendment
Ticker: PAHC · Form: 8-K/A · Filed: Jan 7, 2025 · CIK: 1069899
| Field | Detail |
|---|---|
| Company | Phibro Animal Health Corp (PAHC) |
| Form Type | 8-K/A |
| Filed Date | Jan 7, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, financial-reporting, exhibits
Related Tickers: PAHC
TL;DR
Phibro Animal Health (PAHC) filed an 8-K/A for their Oct 31, 2024 financials - likely a correction.
AI Summary
Phibro Animal Health Corporation filed an 8-K/A on January 7, 2025, to amend its previous filing related to its fiscal year ending October 31, 2024. The amendment specifically concerns Item 9.01, Financial Statements and Exhibits, indicating a correction or addition to previously submitted financial information. No specific financial figures or new material events are detailed in this amendment notice itself.
Why It Matters
This filing indicates an update or correction to Phibro Animal Health's financial reporting for the period ending October 31, 2024, which could be important for investors reviewing their financial disclosures.
Risk Assessment
Risk Level: low — This is an amendment to a previous filing, typically for corrections or additions to financial statements and exhibits, and does not introduce new material events or risks.
Key Players & Entities
- Phibro Animal Health Corporation (company) — Registrant
- October 31, 2024 (date) — Fiscal year end being amended
- January 7, 2025 (date) — Filing date of the amendment
- Item 9.01 (other) — Section of the 8-K/A being amended
FAQ
What is the purpose of this 8-K/A filing?
This 8-K/A filing is an amendment to a previous report, specifically concerning Item 9.01 (Financial Statements and Exhibits) for the fiscal year ending October 31, 2024.
What specific financial information is being amended?
The filing indicates an amendment related to 'Financial Statements and Exhibits' but does not specify the exact nature of the correction or addition within this notice.
When was the original report filed or effective?
The original report pertains to the fiscal year ending October 31, 2024, and this amendment was filed on January 7, 2025.
What is the company's full legal name and state of incorporation?
The company's full legal name is Phibro Animal Health Corporation, and it is incorporated in Delaware.
What is the company's principal executive office address?
The principal executive offices are located at Glenpointe Centre East, 3rd Floor, 300 Frank W. Burr Boulevard, Suite 21, Teaneck, New Jersey 07666-6712.
Filing Stats: 990 words · 4 min read · ~3 pages · Grade level 14.2 · Accepted 2025-01-07 16:35:25
Key Financial Figures
- $0.0001 — hich registered Class A Common Stock, $0.0001 par value per share PAHC NASDAQ Sto
Filing Documents
- pahc-20241031x8ka.htm (8-K/A) — 40KB
- pahc-20241031xex23d1.htm (EX-23.1) — 2KB
- pahc-20241031xex99d1.htm (EX-99.1) — 291KB
- pahc-20241031xex99d2.htm (EX-99.2) — 251KB
- pahc-20241031xex99d3.htm (EX-99.3) — 578KB
- 0001558370-25-000053.txt ( ) — 1372KB
- pahc-20241031.xsd (EX-101.SCH) — 3KB
- pahc-20241031_lab.xml (EX-101.LAB) — 16KB
- pahc-20241031_pre.xml (EX-101.PRE) — 10KB
- pahc-20241031x8ka_htm.xml (XML) — 5KB
01 FINANCIAL STATEMENTS AND EXHIBITS
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS. (a) Financial Statements of Business Acquired The audited Special Purpose Statements of Assets Acquired and Liabilities Assumed of the MFA Product Portfolio of Zoetis as of December 31, 2023 and December 31, 2022 and Special Purpose Statements of Revenue and Direct Expenses for the years ended December 31, 2023 and December 31, 2022, and the notes related thereto, are filed as Exhibit 99.1 to this Form 8-K/A and are incorporated herein by reference. The Special Purpose Statements of Assets Acquired and Liabilities Assumed of the MFA Product Portfolio of Zoetis as of June 30, 2024 (unaudited) and December 31, 2023 and Interim Special Purpose Statements of Revenue and Direct Expenses for the six months ended June 30, 2024 (unaudited) and 2023 (unaudited), and the notes related thereto, are filed as Exhibit 99.2 to this Form 8-K/A and are incorporated herein by reference. (b) Pro Forma Financial Information The unaudited pro forma condensed combined financial information of the Company and the MFA Product Portfolio of Zoetis for and as of the year ended June 30, 2024, and the notes related thereto, are filed as Exhibit 99.3 to this Form 8-K/A and are incorporated herein by reference. (d) Exhibits Exhibit Number Description 23.1 Consent of KPMG LLP 99.1 A udited Special Purpose Statements of Assets Acquired and Liabilities Assumed of the MFA Product Portfolio of Zoetis as of December 31, 2023 and December 31, 2022 and Special Purpose Statements of Revenue and Direct Expenses for the years ended December 31, 2023 and December 31, 2022, and the notes related thereto. 99.2 Special Purpose Statements of Assets Acquired and Liabilities Assumed of the MFA Product Portfolio of Zoetis as of June 30, 2024 (unaudited) and December 31, 2023 and Interim Special Purpose Statements of Revenue and Direct Expenses for the six months ended June 30, 2024 (unaudited) and 2023 (unaudited), and the notes related thereto.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. PHIBRO ANIMAL HEALTH CORPORATION Registrant Date: January 7, 2025 By: /s/ Judith Weinstein Name: Judith Weinstein Title: Senior Vice President, General Counsel and Corporate Secretary